Silence Therapeutics (SLN) Income from Continuing Operations (2020 - 2025)
Historic Income from Continuing Operations for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to -$21.0 million.
- Silence Therapeutics' Income from Continuing Operations rose 4651.43% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 2320.54%. This contributed to the annual value of -$45.3 million for FY2024, which is 1562.71% up from last year.
- As of Q3 2025, Silence Therapeutics' Income from Continuing Operations stood at -$21.0 million, which was up 4651.43% from -$27.4 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Income from Continuing Operations registered a high of $12.3 million during Q4 2024, and its lowest value of -$39.2 million during Q3 2024.
- In the last 5 years, Silence Therapeutics' Income from Continuing Operations had a median value of -$16.6 million in 2021 and averaged -$16.5 million.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first soared by 16622.85% in 2024, then tumbled by 56837.47% in 2025.
- Quarter analysis of 5 years shows Silence Therapeutics' Income from Continuing Operations stood at -$15.1 million in 2021, then dropped by 16.64% to -$17.7 million in 2022, then decreased by 5.23% to -$18.6 million in 2023, then surged by 166.23% to $12.3 million in 2024, then tumbled by 270.36% to -$21.0 million in 2025.
- Its last three reported values are -$21.0 million in Q3 2025, -$27.4 million for Q2 2025, and -$28.5 million during Q1 2025.